TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03679481

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
Study: NCT02615106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 7.5 mg/m2/day, day 1-14

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
Description: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
Study: NCT03249896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habits-GDM mobile app
Description: The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
Study: NCT01556945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02
Description: The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02
Description: The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02
Description: The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
Study: NCT00538265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus, ATG
Description: immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)
Study: NCT01556945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Description: The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Description: The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
Study: NCT00538265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG+mycophénolate mofétil+tacrolimus
Description: immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months.
Study: NCT01556945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Description: The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
Study: NCT04300374

Intervention type: OTHER
Intervention: The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively
Description: routine remifentanil infusion during general anesthesia
Study: NCT01556945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS02 adjuvant alone
Description: AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS02 adjuvant alone
Description: AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Malaria challenge
Description: Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
Study: NCT02580006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPORON
Description: single dose administration subcutaneously
Study: NCT01556945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
Study: NCT02580006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPORON
Description: single dose administration subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: single dose administration subcutaneously
Study: NCT01556945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
Study: NCT02580006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: single dose administration subcutaneously
Study: NCT02772497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv aflibercept
Description: Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
Study: NCT02665442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Stylet - EsoSure
Description: The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
Study: NCT04011436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening program
Description: Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Strengthening program
Description: Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises
Study: NCT00698516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Description: 2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
Study: NCT02272010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Diet
Description: Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Diet
Description: Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
Study: NCT00513019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal (lamotrigine)
Description: once daily from beginning to end of study. Dosage varies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study: NCT00807222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine dimesylate
Description: Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lisdexamfetamine dimesylate
Description: Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
Study: NCT00677456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R-Y reconstruction after total gastrectomy
Description: Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: P-Y reconstruction after total gastrectomy
Description: Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
Study: NCT01835431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
Study: NCT01466140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Writing down request for help
Description: Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
Study: NCT00926588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stepped care
Description: Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
Study: NCT04218123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Daily oral intake 37.5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Daily oral intake
Study: NCT00470184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: IV

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative Study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative Study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative Study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Metastatic growth control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Examination of tissue type

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Tissue removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Tumor shrinkage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Correlative Study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergoing radiation therapy
Study: NCT00677456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pouch reconstruction after total gastrectomy
Description: Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
Study: NCT00315354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Description: Feeding protocol, all foods prepared in a metabolic kitchen
Study: NCT00677456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: P-I reconstruction after total gastrectomy
Description: Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
Study: NCT01489020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: subcutaneous immunotherapy with DPT extract
Description: Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: subcutaneous immunotherapy with DPT extract
Description: Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: subcutaneous immunotherapy with DPT extract
Description: Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous depot placebo
Description: Increasing doses of subcutaneous depot placebo in three different scales

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous depot placebo
Description: Increasing doses of subcutaneous depot placebo in three different scales

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous depot placebo
Description: Increasing doses of subcutaneous depot placebo in three different scales
Study: NCT02158650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Based Informed Consent
Study: NCT00777803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))
Description: NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA (Vistabel®)
Description: OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
Study: NCT02873286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline, sterile

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline, sterile

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline, sterile
Study: NCT04535739

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: prophylactic cranial irradiation
Description: 25Gy/2.5Gy/10f were given for PCI patients

Intervention type: RADIATION
Group type: OTHER
Intervention: prophylactic cranial irradiation
Description: 25Gy/2.5Gy/10f were given for PCI patients
Study: NCT03257488

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: type IV portable monitoring (Somnocheck micro Weinmann)
Description: Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: type IV portable monitoring (Somnocheck micro Weinmann)
Description: Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
Study: NCT02930122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra (150mg)
Description: intraarticular administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline intraarticularly
Description: intraarticular administration
Study: NCT01958177

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
Description: Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
Study: NCT01277237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omacor
Description: Active comparator: omacor 4g/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose tablet
Description: placebo: lactose tablet 4g/day
Study: NCT00824174

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 1 questionnaire, about 15-20 minutes.
Study: NCT00315354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat diet
Description: Feeding protocol, all foods prepared in a metabolic kitchen
Study: NCT01853254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing \< 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
Study: NCT03494374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCBL orthosis
Description: toe walking exercise
Study: NCT04294979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The rehabilitation program will consist of both passive and active therapeutic exercises specifically aimed at restoring or maintaining muscular flexibility, range of motion, balance, coordination of movements, postural passages and transfers, and ambulation. . Furthermore, advanced robotic therapy such as Lokomat® exoskeleton (Hocoma AG, Volketswil, Switzerland), Biodex® Stability System (BSS, Biodex, Inc, Shirley, NY), G-EO System™ (Reha Technology AG, Olten, Svizzera) and Indego® Therapy (Parker USA), will be used to personalize rehabilitation treatment.